Unlike melittin, promelittin has minimal cytotoxicity in normal physiological conditions but can be activated by matrix metalloproteinase 2 (MMP‐2) that is enriched in the tumor microenvironment.14 This activation triggers release of melittin, which, in turn, kills surrounding tumor cells. The gene discussed is MMP2; the disease is neoplasm.